Medications Acting On Platelets

Abstract

Additionally involved in blood clotting and wound healing are platelets. Antiplatelet medications prevent blood clots from forming. These medications are essential, especially for heart-related conditions including myocardial infarction and stroke. An antiplatelet medication called aspirin (NSAID) inhibits the enzyme cyclooxygenase (CoX). to stop the synthesis of the potent platelet aggregator thromboxane A2. ADP receptor inhibitors include clopidogrel and prasugrel. These medications reduce the amplification of platelet aggregation and obstruct ASP-mediated platelet activation. Patients with acute coronary syndromes and those having percutaneous coronary procedures are the target populations for these medications. Two glycoprotein IIb/III inhibitors, tirofiban and abciximab, target a particular stage of the platelet aggregation process. In order to avoid abrupt artery closure during cardiac surgeries, glycoprotein IIb/IIIa inhibitors are specially employed. Phosphodiesterase inhibitors like Clostazol raise intracellular cAMP levels, which helps with platelet inhibition. High cAMP levels obstruct both platelet aggregation and activation. Cilostazol is an effective medication, especially for peripheral arterial disease and intermittent claudications. One thromboxane synthetase inhibitor called picotamide prevents the synthesis of thromboxane A2, which reduces platelet activation and the risk of clot formation. Ultimately, it is determined that medications that affect platelets are essential for treating a variety of cardiovascular diseases and preventing thrombotic episodes.